Current News Thursday, July 2, 2009 Biotech Pharma
avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
LUMBY, BC, July 2 /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink Sheets:... more
Oncolytics Biotech(R) Inc. Completes Patient Enrolment in U.K. Combination REOLYSIN(R) and Paclitaxel/Carboplatin Head and Neck Cancer Trial
CALGARY, July 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)... more
CombinatoRx and Neuromed Sign Merger Agreement
- Merger to Create a Sustainable Biotechnology Company: Brings Together
Significant Product... more
Multi-Cultural
AWS Spectrum Critical for the Growth of Mobile Broadband Across the Americas According to GSMA-Backed Research
New research estimates 177.8 million AWS subscribers by end of 2013 across the US, Canada and Latin America
LONDON, July 2 /PRNewswire/ -- The licensing of the Advanced Wireless Services (AWS) band* will... more
Hola Mexico Film Festival USA '09 and Cinelatino Announce Audience Choice Award Winner
Cinelatino 2009 Audience Choice Award is Festival's Only Award
NEW YORK, July 2 /PRNewswire/ -- The multi-city Hola Mexico Film Festival USA '09 and Cinelatino,... more
NASA Astronaut Starts Agency's First Bilingual Twitter
HOUSTON, July 2 /PRNewswire-USNewswire/ -- NASA astronaut Jose Hernandez, set to fly aboard space... more
FDA
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
- Multaq(R) approved to reduce the risk of cardiovascular hospitalization in patients with atrial fibrillation or atrial flutter -- U.S. commercial launch planned for the summer of 2009 -
PARIS, July 2 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced... more
Nephros Receives 510k Approval for Dual Stage Ultrafilters
RIVER EDGE, N.J., July 2 /PRNewswire-FirstCall/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a... more
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
VYVANSE is the first stimulant to establish duration of efficacy from two hours up to 14 hours... more
| 
